Jan de Backer – CEO, Fluidda
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Address: Groeningenlei 132
2550 Kontich
Groeningenlei 132, 2550 Kontich,Belgium
Tel: +32 3 450 87 20
FluidDA acts as a CRO to support the implementation of the FluidDA imaging biomarkers into clinical trials and clinical practice. To offer a high quality service, FluidDA employs experts in all required fields from medical doctors to biomedical scientists and engineers. A complete package is offered to manage a study from design to (scientific) reporting.
FluidDA has experience in pulmonology, respiratory drug delivery, sleep medicine, maxillofacial surgery and cardiovascular. The company collects stores, manages and analyzes data coming from a variety of imaging modalities such as CT, MRI, Cone Beam CT, SPECT and ultrasound. From clinical studies, FluidDA has gained extensive experience in scanning protocols to achieve proper image quality. FluidDA can write or assist in writing protocols for clinical imaging studies according to GCP guidelines as well as analyzing and writing of study results in international peer reviewed journals.
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Dr De Backer looking into your background, we see that you have a background in aerospace engineering and applied biomedical computational fluid dynamics that is riddled with awards for your…
Speaking exclusively to PharmaBoardroom, Pedro Facon outlines the scope and aims of the new medicines roadmap that NIHDI has recently presented to the Belgian Ministry of Health following extensive stakeholder…
An Van Gerven took the reins of Pfizer’s BeLux affiliate just 9 months ago after a diverse range of roles at the company over the course of 12 years. She…
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly,…
The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes…
Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
Marc Gryseels of BACHI, Belgium’s over-the-counter (OTC) medicines association, highlights the organisation’s mission and vision, the key trends at play within the Belgian consumer healthcare market, and his industry’s significant…
See our Cookie Privacy Policy Here
